

1 **Estimation of mean pulmonary artery pressure by cardiovascular**
2 **magnetic resonance four-dimensional flow and compressed sensing**

3
4 Goran Abdula^{*1,2}, Pernilla Bergqvist^{*1,2}, Jenny Castaings^{1,2}, Alexander Fyrdahl^{1,2},
5 Daniel Giese³, Ning Jin⁴, Frederik Testud⁵, Peder Sörensson^{1,6}, Andreas Sigfridsson^{1,2},
6 Martin Ugander^{§1,2,7,8}, David Marlevi^{§1,9,#}

7
8 ¹Dept. of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden

9 ²Dept. of Clinical Physiology, Karolinska University Hospital, Stockholm, Sweden

10 ³Magnetic Resonance, Siemens Healthcare, GmbH, Erlangen, Germany

11 ⁴Cardiovascular MR R&D, Siemens Medical Solutions USA, Inc, Cleveland, OH, USA

12 ⁵Siemens Healthcare AB, Malmö, Sweden

13 ⁶Dept. of Cardiology, Karolinska University Hospital, Stockholm, Sweden

14 ⁷Kolling Institute, Royal North Shore Hospital, St Leonards, Sydney, Australia

15 ⁸University of Sydney, Sydney, Australia

16 ⁹Institute for Medical Engineering and Science, Massachusetts Institute of Technology,
17 Cambridge, MA, USA

18
19 * denotes equal contribution as first author

20 § denotes equal contribution as last author

21 # denotes corresponding author

23 **Abstract**

24 **Background:** Four-dimensional (4D) phase-contrast cardiovascular magnetic resonance
25 (CMR) allows for precise non-invasive estimation of mean pulmonary artery pressure
26 (mPAP) by estimating the duration of pathological vortex persistence in the main pulmonary
27 artery. This has previously been achieved with compressed sensing acceleration of a multiple
28 two-dimensional (CS-M2D) flow sequence, but acquisition using a true time-resolved 3D
29 excitation (CS-4D) offers theoretical advantages including spatiotemporal coherence. This
30 study aimed to validate a state-of-the-art CS-4D sequence with a previously utilized CS-M2D
31 sequence for estimating mPAP, and compare both to right heart catheterization (RHC).

32 **Methods:** The study included patients clinically referred for CMR (n=45), of which a
33 subgroup (n=20) had prior mPAP of >16 mmHg confirmed by RHC. CMR was performed at
34 1.5T using CS-M2D and CS-4D sequences covering the main pulmonary artery. mPAP was
35 estimated using a previously published linear relationship between vortex duration and
36 mPAP. Agreement between CS-M2D and CS-4D estimates was quantified, including analysis
37 of intra- and interobserver variabilities. The diagnostic performance of CS-M2D and CS-4D
38 in predicting mPAP was further compared to gold-standard RHC. **Results:** CS-M2D and CS-
39 4D both had average scan durations under 3 minutes (175±36 and 135±34 seconds,
40 respectively). Estimated mPAP by CS-4D and CS-M2D were strongly correlated ($R^2=0.93$,
41 $p<0.001$), with negligible mean±SD bias (0.0±2.7 mmHg) and good reproducibility. There
42 was excellent agreement with RHC for both CS-M2D ($R^2=0.92$, $p<0.001$, bias 0.6±3.1
43 mmHg) and CS-4D ($R^2=0.86$, $p<0.001$, bias 1.1±4.5 mmHg). **Conclusions:** CS-4D and CS-
44 M2D sequences effectively yield interchangeable non-invasive estimations of mPAP, with
45 excellent agreement compared to invasive RHC. They can both be acquired in a scan time
46 applicable to clinical workflow, offering a promising tool for non-invasive mPAP estimation
47 in clinical practice.

48 **Background**

49 4D flow cardiovascular magnetic resonance (CMR) is a non-invasive imaging modality
50 allowing for comprehensive assessment of full-field blood flow along arbitrary flow
51 directions and throughout the entire cardiac cycle (1). The technique has been utilized across
52 a variety of cardiovascular applications (2-5). In the setting of complex multidirectional
53 flows, 4D imaging has shown advantages when compared to traditional 2D phase contrast
54 imaging for both quantifying (6) and visualizing multidirectional flow (7). Moreover, 4D
55 flow enables advanced hemodynamic assessment related to blood flow pattern, such as
56 vorticity and helicity (8). In particular, recent studies have indicated the potential of using
57 volumetric flow quantification using multiple stacked 2D (M2D) phase-contrast imaging with
58 time-resolved three-directional velocity encoding to non-invasively quantify mean pulmonary
59 artery pressure (mPAP) (9, 10) – a key diagnostic marker in diagnosing and prognosticating
60 pulmonary hypertension (11).

61 Non-invasive estimation of mPAP depends on identification of vortical flow patterns in the
62 main pulmonary artery, which can be performed in multiple ways. Previous work has utilized
63 M2D imaging whereby 2D slices are stacked together to form a reconstructed 3D volume
64 (12). By comparison, a true 4D acquisition, where the entire volume is acquired using a slab-
65 selective excitation scheme and partition encoding, bears a number of theoretical advantages
66 including temporal and spatial coherence, flexibility in acquiring isotropic voxels, and
67 avoiding slice crosstalk. Furthermore, as non-invasive estimation of mPAP requires full
68 coverage of the main pulmonary artery, its clinical adoption has been hindered by a relatively
69 long scan time (13). The implementation of compressed sensing (CS) acceleration now
70 promises acquisition in clinically acceptable scan times (14, 15). However, a direct
71 comparison between M2D and true 4D flow have yet to be performed, and likewise, the
72 accuracy of CS accelerated 4D (CS-4D) flow in detection of vortical flow and thereby

73 estimation of mPAP remains unknown. Therefore, the aim of this study was to perform a
74 comparison of CS accelerated M2D (CS-M2D) and CS-4D for estimating mPAP, with
75 validation against right heart catheterization (RHC) in a sub-cohort of subjects with available
76 invasive reference data.

77

78

79 **Materials and Methods**

80 ***Study Participants***

81 The study cohort consisted of two groups. In the first group, thirty-five patients with referral
82 for cardiac magnetic resonance (CMR) imaging who were suspected of having pulmonary
83 hypertension (PH) were included. Reasons for suspected PH were known left ventricular
84 systolic dysfunction or prior echocardiography revealing high systolic pulmonary artery
85 pressure (sPAP). To validate CMR 4D flow estimated mPAP against the invasive reference
86 standard RHC, a second group of 20 patients with mPAP >16 mmHg confirmed by RHC
87 were enrolled. The cutoff of 16 mmHg was chosen since this cutoff represents the lowest
88 pressure required for vortex formation (9). Patients with known contraindications for CMR,
89 arrhythmia, pacemaker, other cardiac implants, or valvular prosthesis were excluded. All
90 subjects provided written informed consent, and the study was approved by the Swedish
91 Ethical Review Authority (DNR: 2015/2106-31/1).

92 ***CMR Imaging***

93 CMR images were acquired using either a MAGNETOM Aera 1.5T (n=32) or MAGNETOM
94 Sola 1.5T (n=23) (Siemens Healthineers AG, Erlangen, Germany). Anatomical and
95 functional imaging was performed using breath-held cine imaging with balanced steady-state
96 free precession (bSSFP) in both short and long axis views. Flow imaging of the main
97 pulmonary artery (MPA) was acquired using compressed sensing (CS) accelerated time-
98 resolved phase contrast imaging with three-directional velocity encoding, both using multiple
99 2D slices (CS-M2D) and volumetric excitation with partition encoding (CS-4D). The CS-
100 M2D approach used 3 averages to reduce respiratory motion artifacts, whereas the CS-4D
101 approach used either a crossed-pair or a pencil-beam respiratory navigator placed over the
102 liver dome. **Table 1** shows a summary of imaging parameters used for both scanners.

103 **Image Analysis**

104 Left ventricular size, function, and mass were evaluated by manual segmentation of end-
105 diastolic and end-systolic borders on the bSSFP cine 4-chamber view and short axis stacks
106 using syngo.via (Siemens Healthineers AG, Erlangen, Germany). The basal dimension of the
107 right ventricle (RV) at end-diastole (RVDd) and RV longitudinal function were determined
108 by measuring tricuspid annular plane excursion (TAPSE) in the cine four-chamber view.
109 Scan duration was recorded using a timer in a subgroup of patients, since actual scan duration
110 was not stored in the dicom meta data.

111 For the hemodynamic image analysis, CS-M2D and CS-4D flow data were anonymized. The
112 vortical blood flow in the MPA was assessed using a research software package (4D Flow,
113 Siemens Healthineers AG, Erlangen, Germany) in a randomized order. The datasets were
114 pre-processed by applying background phase correction following cropping of spatially
115 aliased structure if needed. The presence of pathological vortical blood flow was identified
116 using multi-planar reconstructed 3-dimensional vector fields, see **Figure 1**. Vortex duration
117 was defined as the percentage of the cardiac phases where vortical blood flow could be
118 identified (12). Subsequently, mPAP was calculated using a previously determined empirical
119 formula (9):

$$mPAP_{(CMR)}(mmHg) = \frac{Vortex\ duration\ (\%) + 25.44}{1.59} \quad (7)$$

120 The 4D flow analysis was performed for the first cohort by two independent readers (PB and
121 a subset by GA), and for the second cohort by a single reader (GA). Analysis was
122 consistently performed interchangeably on both CS-M2D and CS-4D datasets in a
123 randomized fashion. Intra- and interobserver variability was assessed by selecting n=20
124 patients in the first cohort for which multiple readings were performed.

125

126 ***Statistical analysis***

127 Continuous variables were reported as mean \pm standard deviation (SD) for normally
128 distributed variables, while non-normally distributed variables were reported as median and
129 interquartile range. Categorical variables were reported as frequencies and percentages. To
130 quantify differences between CS-M2D and CS-4D measurements, two-tailed paired Student's
131 t-test was employed. Linear regression and Bland-Altman analysis were used to assess
132 correlations and biases. Further, to quantify agreements between identified frames containing
133 pathological MPA vortices, the Jaccard similarity coefficient was calculated as the mean of
134 the index derived for absence, and presence of pathological MPA vortices, respectively.
135 Intra- and interobserver variability was evaluated by means of Bland-Altman statistics,
136 calculating mean biases with standard deviations, along with the Jaccard similarity coefficient
137 as per above.

138 Statistical testing was performed using SPSS version 27 (IBM Corp., Armonk, NY, USA). A
139 significance level of $p < 0.05$ was utilized for all analyses.

140

141

142 **Results**

143 Of the 55 prospectively included patients, 10 were excluded from analysis owing to the
144 occurrence of arrhythmia during acquisition (n=4, affecting both CS-M2D and CS-4D),
145 unrecoverable phase aliasing (n=2, affecting both CS-M2D and CS-4D), aborted ECG
146 triggering (n=3, affecting CS-4D imaging), or post-scan reconstruction errors (n=1, affecting
147 CS-4D). Excluded acquisition were equally distributed between the two utilized scanners
148 (n=5 excluded from the Aera, n=5 excluded from the Sola). Demographics and CMR
149 characteristics for the remaining 45 patients are summarized in **Table 2**.

150 ***Diagnostic differentiation of pulmonary hypertension***

151 Pulmonary hypertension (PH) defined as an estimated mPAP ≥ 20 mmHg was identified in
152 25/45 (56%) subjects by CS-M2D and 20/45 (44%) subjects by CS-4D. In 86% of the cases,
153 both CS-M2D and CS-4D provided consistent classifications. Discrepancies arose in six
154 subjects: five patients were classified with PH by CS-M2D, and one patient was classified
155 with PH by CS-4D, see **Table 3**. For the subgroup who underwent reference standard
156 invasive RHC (n=20), CS-M2D and RHC classifications agreed perfectly, confirming PH in
157 18 patients and ruling it out in two (mPAP <20 mmHg). Conversely, CS-4D exhibited
158 discrepancies in three cases, two false positives and one false negative. An overview of the
159 classification by CS-M2D vs CS-4D is given in **Figure 2**.

160 ***Quantification of mPAP***

161 The time between RHC and CMR was 61 [40-142] days. Both CS-M2D and CS-4D
162 approaches demonstrated excellent agreement for non-invasive estimation of mPAP with a
163 high level of agreement ($R^2=0.93$, $p<0.001$) and low bias (0.0 ± 2.7 mmHg, **Figure 3**). There
164 was no difference between estimated mPAP by CS-M2D and CS-4D in the overall cohort

165 (24.3±9.9 vs. 23.7±9.2 mmHg, $p = 0.15$). The Jaccard similarity coefficient was 0.79 between
166 mPAP estimated by CS-M2D and CS-4D across the entire cohort.

167 *Comparison between estimated mPAP by CMR and RHC*

168 Strong correlations were observed between mPAP measured by RHC and estimated by CS-
169 M2D ($R^2=0.92$, $p<0.001$), with an effective absence of any bias and good precision (0.6 ± 3.1
170 mmHg, **Figure 4**). CS-4D also exhibited strong correlation with RHC ($R^2=0.86$, $p<0.001$)
171 and a similarly low mean bias and good precision (1.1 ± 4.6 mmHg, **Figure 4**). Estimated
172 mPAP did not differ between CS-M2D, CS-4D, and RHC (CS-M2D vs CS-4D: $p=0.98$; CS-
173 M2D vs RHC: $p=0.80$; CS-4D vs RHC: $p=0.59$).

174 *Reproducibility analysis*

175 From the intraobserver variability analysis, strong agreement was observed for both repeated
176 CS-M2D (mean bias: 0.8 ± 4.4 mmHg; Jaccard similarity index: 0.78) and CS-4D (mean bias:
177 0.8 ± 2.0 mmHg; Jaccard similarity index: 0.79) readings, respectively. For the interobserver
178 variability analysis, similar negligible bias was observed although with higher variation for
179 both repeat CS-M2D (mean bias: 0.3 ± 9.0 mmHg; Jaccard similarity index: 0.54) and CS-4D
180 (mean bias: 1.6 ± 7.7 mmHg; Jaccard similarity index: 0.55) readings, respectively. An
181 overview of the reproducibility readings is provided in **Figure 5**.

182 *Scan time*

183 With estimates taken from a subgroup of 8 patients, average scan duration for CS-M2D and
184 CS-4D were 175 ± 36 s and 135 ± 34 s, respectively.

185

186

187 **Discussion**

188 The main finding of the current study is that both CS-M2D and CS-4D imaging approaches
189 using CMR yield interchangeable results that both represent accurate estimations of mPAP
190 when validated against invasive RHC. These results further highlight the potential of CMR as
191 a non-invasive alternative for diagnosis of pulmonary hypertension; in-line with previous
192 findings in literature (9, 16, 17).

193 In previous studies, CMR-based estimation of mPAP has been performed using the M2D
194 approach without CS acceleration (9, 10, 12). Whilst a recent study showed that CS
195 acceleration had non-inferior performance (16), the current study represents the first head-to-
196 head comparison between CS-M2D and CS-4D, and the first comparison of these techniques
197 to invasive RHC. Here, we aimed to replicate the previously published CS-M2D sequence,
198 with the CS-4D representing a state-of-the-art comparator. As highlighted in **Table 1**, this
199 resulted in a number of differences relating to effective voxel size, temporal resolution, and
200 overall acquisition time. Specifically, CS-M2D used a voxel size of $1.8 \times 1.8 \times 6.0 \text{ mm}^3$ as
201 compared to CS-4D at $2.0 \times 2.5 \times 2.5 \text{ mm}^3$. As such, flow coverage by CS-4D is almost twice as
202 dense as compared to CS-M2D in the slice direction, with only minor differences in in-plane
203 resolution. CS-4D would thus have the theoretical ability to quantify finer flow details
204 compared to CS-M2D. Furthermore, there are slight differences in temporal resolution in the
205 utilized acquisition settings, and the nature of CS-M2D imaging involves spatially contiguous
206 but temporally disparate slice acquisitions. This presents theoretical challenges for the CS-
207 M2D approach, particularly in transient or complex anatomies and flows. However, the
208 current study highlights the effectively equivalent capabilities of CS-4D and CS-M2D for
209 non-invasive estimation of mPAP despite these theoretical differences and challenges.

210 Early detection of PH is associated with improved prognosis (18), however, the majority of
211 PH patient diagnosed present at an advance stage (NYHA class III and IV), leaving early
212 detection a remaining and urgent clinical challenge (19). Early detection is typically
213 attempted using echocardiography. However, it has been shown that identifying PH by 4D
214 flow analysis by CMR has twice the diagnostic yield compared to echocardiography (20), and
215 this increased diagnostic performance has been confirmed compared to RHC (17).
216 Furthermore, identifying PH is a central component of assessing diastolic dysfunction, which
217 plays a central role in the diagnosis and therapeutic evaluation in heart failure with preserved
218 ejection fraction (HFpEF). Indeed, estimation of mPAP by 4D flow analysis can be used to
219 perform grading of diastolic dysfunction by CMR, and this has shown excellent agreement
220 compared to echocardiography (21). These described clinical applications of 4D flow
221 analysis by CMR to date have all used M2D acquisition without CS acceleration, and the
222 results of the current study now provide the field with important confidence to use CS to
223 drastically reduce acquisition time from an average of 9 minutes to under 3 minutes, which
224 provides valuable improvements in clinical throughput capacity for CMR imaging facilities.
225 Insights into clinical utility were also provided by the reproducibility study. As presented in
226 **Figure 5**, negligible bias was reported in an intraobserver setting, and in the interobserver
227 setting observer bias was kept below 1.6 mmHg across all subjects and acquisition sequences,
228 respectively. Nevertheless, increased variance was observed in the interobserver setting; a
229 finding aligning with the nature of multiple observers, but still highlighting challenges
230 associated with manual image interpretation. Recent developments on semi-automatic or
231 even fully automatic vortex detection in the setting of pulmonary flow imaging has shown
232 high clinical potential (22, 23), herein offering a promising path towards mitigating reader
233 bias and maintaining accurate estimation of performance.

234 The current study has some limitations that need to be acknowledged. First, a relatively small
235 number of patients were included, in particular in the subgroup that underwent RHC. As
236 such, further validation in larger cohorts could be of benefit, and would aid in the
237 understanding of how the current results can generalize into other centers or across larger and
238 differently composed populations. That said, it has already been shown that estimating mPAP
239 with the M2D approach is excellently accurate and robust across all subtypes of PH (9).
240 Second, pathological vortex detection as performed in the current study is currently a
241 manually performed method, which is not only time consuming, but also leaves room for
242 observer variations as highlighted in the reproducibility study. As noted above, efforts to
243 reduce observer dependence have recently been presented through incorporation of semi-
244 automatic or fully automatic vortex detection algorithms (22, 23). As such, the current results
245 provide the basis and confidence for understanding accuracy and sequence performance, from
246 which further optimization can be envisioned.

247 **Conclusion**

248 CS-accelerated CMR 4D flow analysis provides means for accurate and clinically feasible
249 non-invasive assessment of mPAP using either CS-M2D or CS-4D approaches, opening for a
250 more accessible way of diagnosing PH compared to invasive catheterization.

251

252 **List of abbreviations**

253 4D – Four-dimensional

254 CMR – cardiovascular magnetic resonance

255 mPAP – mean pulmonary artery pressure

256 CS – compressed sensing

257 CS-M2D – compressed sensing multiple two-dimensional (flow sequence)

258 CS-4D – compressed sensing time-resolved three-dimensional (flow sequence)

259 RHC – right heart catheterization

260 bSSFP – balanced steady-state free precession

261 MPA – main pulmonary artery

262 RV – right ventricle

263 TAPSE – tricuspid annular plane excursion

264

265 **Declarations**

266 *Ethics approval and consent to participate*

267 All subjects provided written informed consent, and the study was approved by the Swedish
268 Ethical Review Authority (DNR: 2015/2106-31/1).

269 *Consent for publication*

270 Not applicable.

271 *Availability of data and materials*

272 The datasets used and/or analysed during the current study are available from the
273 corresponding author on reasonable request.

274 *Competing interests*

275 D.G., N.J. and F.T. are employees of Siemens Healthineers. G.A., P.B., J.C., A.F., P.S., A.S.,
276 M.U., and D.M. are all either employed by or affiliated with Karolinska University Hospital,
277 which has an institutional research and development agreement regarding cardiovascular
278 magnetic resonance with Siemens Healthineers.

279 *Funding*

280 This work was funded in part by the European Union (ERC, MultiPRESS, 101075494).
281 Views and opinions expressed are those of the authors and do not reflect those of the
282 European Union or the European Research Council Executive Agency. Funding was also
283 provided in part by New South Wales Health, Heart Research Australia, University of
284 Sydney.

285 *Author's contributions*

286 D.M. and M.U. conceived of the study, with G.A., P.B., M.U. and D.M. involved in study
287 design, patient recruitment, and primary image and statistical analysis. D.G., N.J., and F.T.
288 were involved in sequence acquisition design, with A.F., A.S., and J.C. leading local
289 implementation and guidance on image acquisition and analysis. D.M., M.U., A.S., and P.S.
290 supervised P.B and G.A., taking part in analysis and preliminary data assessment. All authors
291 were involved in manuscript drafting, and all authors approved of the final manuscript.

292 ***Acknowledgement***

293 Not applicable.

294


295

296 References

- 297 1. Markl M, Chan FP, Alley MT, Wedding KL, Draney MT, Elkins CJ, et al. Time-
298 resolved three-dimensional phase-contrast MRI. *J Magn Reson Imaging*. 2003;17(4):499-
299 506.
- 300 2. Barker AJ, Staehle F, Bock J, Jung BA, Markl M. Analysis of complex cardiovascular
301 flow with three-component acceleration-encoded MRI. *Magn Reson Med*. 2012;67(1):50-61.
- 302 3. Goldberg A, Jha S. Phase-contrast MRI and applications in congenital heart disease.
303 *Clin Radiol*. 2012;67(5):399-410.
- 304 4. Markl M, Kilner PJ, Ebbers T. Comprehensive 4D velocity mapping of the heart and
305 great vessels by cardiovascular magnetic resonance. *J Cardiovasc Magn Reson*. 2011;13(1):7.
- 306 5. Stankovic Z, Allen BD, Garcia J, Jarvis KB, Markl M. 4D flow imaging with MRI.
307 *Cardiovasc Diagn Ther*. 2014;4(2):173-92.
- 308 6. Nordmeyer S, Riesenkampff E, Messroghli D, Kropf S, Nordmeyer J, Berger F, et al.
309 Four-dimensional velocity-encoded magnetic resonance imaging improves blood flow
310 quantification in patients with complex accelerated flow. *J Magn Reson Imaging*.
311 2013;37(1):208-16.
- 312 7. Markl M, Draney MT, Hope MD, Levin JM, Chan FP, Alley MT, et al. Time-
313 resolved 3-dimensional velocity mapping in the thoracic aorta: visualization of 3-directional
314 blood flow patterns in healthy volunteers and patients. *J Comput Assist Tomogr*.
315 2004;28(4):459-68.
- 316 8. Bächler P, Pinochet N, Sotelo J, Crelier G, Irrazaval P, Tejos C, et al. Assessment of
317 normal flow patterns in the pulmonary circulation by using 4D magnetic resonance velocity
318 mapping. *Magn Reson Imaging*. 2013;31(2):178-88.
- 319 9. Reiter G, Reiter U, Kovacs G, Olschewski H, Fuchsjäger M. Blood flow vortices
320 along the main pulmonary artery measured with MR imaging for diagnosis of pulmonary
321 hypertension. *Radiology*. 2015;275(1):71-9.
- 322 10. Reiter G, Reiter U, Kovacs G, Kainz B, Schmidt K, Maier R, et al. Magnetic
323 Resonance-Derived 3-Dimensional Blood Flow Patterns in the Main Pulmonary Artery as a
324 Marker of Pulmonary Hypertension and a Measure of Elevated Mean Pulmonary Arterial
325 Pressure. *Circ Cardiovasc Imaging*. 2008;1(1):23-30.
- 326 11. Kimura M, Taniguchi H, Kondoh Y, Kimura T, Kataoka K, Nishiyama O, et al.
327 Pulmonary Hypertension as a Prognostic Indicator at the Initial Evaluation in Idiopathic
328 Pulmonary Fibrosis. *Respiration*. 2012;85(6):456-63.
- 329 12. Reiter U, Reiter G, Kovacs G, Stalder AF, Gulsun MA, Greiser A, et al. Evaluation of
330 elevated mean pulmonary arterial pressure based on magnetic resonance 4D velocity
331 mapping: comparison of visualization techniques. *PLoS One*. 2013;8(12):e82212.
- 332 13. Bissell MM, Raimondi F, Ait Ali L, Allen BD, Barker AJ, Bolger A, et al. 4D Flow
333 cardiovascular magnetic resonance consensus statement: 2023 update. *J Cardiovasc Magn
334 Reson*. 2023;25(1):40.
- 335 14. Ma LE, Markl M, Chow K, Huh H, Forman C, Vali A, et al. Aortic 4D flow MRI in 2
336 minutes using compressed sensing, respiratory controlled adaptive k-space reordering, and
337 inline reconstruction. *Magn Reson Med*. 2019;81(6):3675-90.
- 338 15. Bollache E, Barker AJ, Dolan RS, Carr JC, van Ooij P, Ahmadian R, et al. k-t
339 accelerated aortic 4D flow MRI in under two minutes: Feasibility and impact of resolution, k-
340 space sampling patterns, and respiratory navigator gating on hemodynamic measurements.
341 *Magn Reson Med*. 2018;79(1):195-207.
- 342 16. Abdula G, Ramos JG, Marlevi D, Fyrdahl A, Engblom H, Sörensson P, et al. Non-
343 invasive estimation of mean pulmonary artery pressure by cardiovascular magnetic resonance

- 344 in under 2 min scan time. *European Heart Journal - Imaging Methods and Practice*.
345 2023;1(1).
- 346 17. Ramos JG, Wieslander B, Fyrdahl A, Reiter G, Reiter U, Jin N, et al. Pulmonary
347 Hypertension by Catheterization Is More Accurately Detected by Cardiovascular Magnetic
348 Resonance 4D-Flow Than Echocardiography. *JACC Cardiovasc Imaging*. 2023;16(4):558-9.
- 349 18. Lau EM, Humbert M, Celmaj DS. Early detection of pulmonary arterial
350 hypertension. *Nat Rev Cardiol*. 2015;12(3):143-55.
- 351 19. Ling Y, Johnson MK, Kiely DG, Condliffe R, Elliot CA, Gibbs JS, et al. Changing
352 demographics, epidemiology, and survival of incident pulmonary arterial hypertension:
353 results from the pulmonary hypertension registry of the United Kingdom and Ireland. *Am J*
354 *Respir Crit Care Med*. 2012;186(8):790-6.
- 355 20. Ramos JG, Fyrdahl A, Wieslander B, Reiter G, Reiter U, Jin N, et al. Cardiovascular
356 magnetic resonance 4D flow analysis has a higher diagnostic yield than Doppler
357 echocardiography for detecting increased pulmonary artery pressure. *BMC Med Imaging*.
358 2020;20(1):28.
- 359 21. Ramos JG, Wieslander B, Fyrdahl A, Reiter G, Reiter U, Jin N, et al. Pulmonary
360 Hypertension by Catheterization Is More Accurately Detected by Cardiovascular Magnetic
361 Resonance 4D-Flow Than Echocardiography. *JACC Cardiovasc Imaging*.0(0).
- 362 22. Kräuter C, Reiter U, Kovacs G, Reiter C, Masana M, Olschewski H, et al. Automated
363 vortical blood flow-based estimation of mean pulmonary arterial pressure from 4D flow MRI.
364 *Magn Reson Imaging*. 2022;88:132-41.
- 365 23. Sabry M, Lamata P, Sigfridsson A, Keramati H, Fyrdahl A, Ugander M, et al., editors.
366 Vortex Duration Time to Infer Pulmonary Hypertension: In-Silico Emulation
367 and Dependence on Quantification Technique2023; Cham: Springer Nature Switzerland.
368
369

370 **Figures**
371
372



373
374
375 **Figure 1.** Vortical blood flow visualized in the main pulmonary artery in an oblique sagittal
376 view for a patient with pulmonary hypertension (mPAP 35 mmHg by right heart
377 catheterization), using CS-M2D (top row) and CS-4D (bottom row) across four representative
378 time frames out of total 20 cardiac phases. The visualization is using multiplanar reformatted
379 3D velocity vector arrows color-coded for velocity. White arrow indicates a vortex.
380
381


382

Frequency of patients in each group comparing CS-M2D to CS-4D				
CS-M2D		Normal		Increased PA pressure
		No observable vortex	Estimated mPAP <20 mmHg	Estimated mPAP ≥ 20 mmHg
CS-4D		No observable vortex	Estimated mPAP <20 mmHg	Estimated mPAP ≥ 20 mmHg
Normal	No observable vortex	15 (33 %)	0	2 (4%)
	Estimated mPAP <20 mmHg	2 (4 %)	2 (4 %)	3 (7 %)
Increased PA pressure	Estimated mPAP ≥ 20 mmHg	0	1 (2 %)	20 (44 %)

383
384
385
386
387

Figure 2. Distribution of pulmonary artery pressure diagnosis, comparing classification by PA vortex duration detected by CS-M2D and CS-4D.


388
389



390
391
392
393
394
395


Figure 3. Linear regression (a) and (b) Bland-Altman Plots of the estimated mean pulmonary arterial pressures (mPAP) from vortex duration determined by CS-M2P and CS-4D.

396
397



398
399
400
401
402
403
404

Figure 4. Linear regression and Bland-Altman Plots of mean pulmonary arterial pressures (mPAP) measured at right heart catheterization (RHC) and estimated mPAP by CS-M2D method (a-b) and estimated mPAP by CS-4D (c-d).



405
406 **Figure 5.** Bland-Altman Plots of mean pulmonary arterial pressures (mPAP) estimated by
407 CS-M2D and by CS-4D, showing intra- (a-b) and interobserver (c-d) variability across a
408 randomly selected subset of n=20 patients.
409
410

411 **Tables**
412
413

Table 1. Sequence parameters of CS-M2D and CS-4D flow imaging at both scanners.

Parameters	CS-M2D		CS-4D	
	Aera 1.5T	Sola 1.5T	Aera 1.5T	Sola 1.5T
Field of view (mm)	340	340	320	320
Voxel size (mm ³)	1.8 x 1.8 x 6.0	1.8 x 1.8 x 6.0	2.0 x 2.5 x 2.5	2.0 x 2.5 x 2.5
Number of Slices	10	10	30	30
Velocity encoding (VENC, cm/s)	90	90	90	90
Bandwidth (Hz/pixel)	449	449	558	558
Flip angle (°)	15	15	15	15
Temporal resolution (ms)	75.24	70.0	58.68	61.1
Reconstructed time frames, n	20	20	20	20
Echo time (ms)	4.10	3.61	2.55	3.0
Repetition time (ms)	6.27	5.83	4.89	5.09
Slice coverage (mm)	60	60	60	60
Acceleration factor	7.7	8.8	6.0	7.6
Respiratory navigator type	-	-	Pencil beam	Cross-pair

414
415
416

417
418

Table 2. Patient demographics and clinical characteristics

Number of patients, n	45
Age, years	55.6 ± 19.3
Female, n (%)	26 (58)
BMI, kg/m ²	24.8 ± 5.2
BSA, m ²	1.9 ± 0.2
Heart rate, beats per minute	71 ± 13
LV EDV, ml	145 [112-191]
LV EDV index ml/m ²	80 [66-90]
LV ESV, ml	59 [39-73]
LV ESV index, ml/m ²	31 [24-42]
LV SV, ml	84 [68-103]
LV SV index ml/m ²	45 [38-53]
LV EF, %	60 [54-64]
LV mass, g	115 [87-144]
LV mass index, g/m ²	60 [50-70]
RVDd, mm	46 [46-51]
TAPSE, mm	24 [21-27]

BMI = body mass index; BSA = body surface area; LV = left ventricular; EDV = end diastolic volume; ESV = end systolic volume; SV = stroke volume; RVDd = right ventricular dimension at end-diastole; TAPSE = tricuspid annular plane excursion.

419

420

421

Table 3. Identification of PH by CS-M2D vs CS-4D: mPAP > 20 mmHg

CS-4D	CS-M2D		
	Non-PH	PH	Total
Non-PH	19 (42%)	5 (11%)	24
PH	1 (2%)	20 (44%)	21
Total	20 (44%)	25 (56%)	45

PH = pulmonary hypertension

422